title: Fibrinogen cleavage by the Streptococcus pyogenes extracellular cysteine protease and generation of antibodies that inhibit enzyme proteolytic activity.
abstract: The extracellular cysteine protease from Streptococcus pyogenes is a virulence factor that plays a significant role in host-pathogen interaction. Streptococcal protease is expressed as an inactive 40-kDa precursor that is autocatalytically converted into a 28-kDa mature (active) enzyme. Replacement of the single cysteine residue involved in formation of the enzyme active site with serine (C192S mutation) abolished detectable proteolytic activity and eliminated autocatalytic processing of zymogen to the mature form. In the present study, we investigated activity of the wild-type (wt) streptococcal protease toward human fibrinogen and bovine casein. The former is involved in blood coagulation, wound healing, and other aspects of hemostasis. Treatment with streptococcal protease resulted in degradation of the COOH-terminal region of fibrinogen alpha chain, indicating that fibrinogen may serve as an important substrate for this enzyme during the course of human infection. Polyclonal antibodies generated against recombinant 40- and 28-kDa (r40- and r28-kDa) forms of the C192S streptococcal protease mutant exhibited high enzyme-linked immunosorbent assay titers but demonstrated different inhibition activities toward proteolytic action of the wt enzyme. Activity of the wt protease was readily inhibited when the reaction was carried out in the presence of antibodies generated against r28-kDa C192S mutant. Antibodies produced against r40-kDa C192S mutant had no significant effect on proteolysis. These data suggest that the presence of the NH(2)-terminal prosegment prevents generation of functionally active antibodies and indicate that inhibition activity of antibodies most likely depends on their ability to bind the active-site region epitope(s) of the protein.
authors.affiliation: Wyeth-Lederle Vaccines, West Henrietta, New York 14586-9728, USA.
authors.forename: Y V
authors.initials: YV
authors.lastname: Matsuka
authors.forename: S
authors.initials: S
authors.lastname: Pillai
authors.forename: S
authors.initials: S
authors.lastname: Gubba
authors.forename: J M
authors.initials: JM
authors.lastname: Musser
authors.forename: S B
authors.initials: SB
authors.lastname: Olmsted
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology*; D002364:Caseins / Q000378:metabolism; D002417:Cattle; D003546:Cysteine Endopeptidases / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism*; D006801:Humans; D051379:Mice; D016297:Mutagenesis, Site-Directed; D010078:Oxazines; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D013297:Streptococcus pyogenes / Q000201:enzymology*; D013379:Substrate Specificity
chemical_list: D000907:Antibodies, Bacterial; D002364:Caseins; D010078:Oxazines; D011993:Recombinant Fusion Proteins; C014180:resorufin; D005340:Fibrinogen; D003546:Cysteine Endopeptidases; C042477:streptopain